YASHI MASAHIRO

Profiles

Profiles

• 氏名

  YASHI MASAHIRO

Affiliation

• Department of Urology, Professor

Research achievements

Published Papers

Original paper
• 5(1), e000666, Jan. 2018

  DOI
• 11, 47-49, Jan. 2017

  DOI
• Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer, Mizuno T, Kamai TAbe HSakamoto SKitajima KNishihara DYuki HKambara TBetsunoh HYashi MFukabori YKaji YYoshida K, BMC Cancer, 15, 1097, Mar. 2015

  DOI
• Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases, Yashi M, Nishihara DMizuno TYuki HMasuda AKambara TBetsunoh HAbe HFukabori YMuraishi OKamai T, Clin Genitourin Cancer, 12(5), e197-e203, Oct. 2014

  DOI
• The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells, Abe H, Kamai THayashi KAnzai NShirataki HMizuno TYamaguchi YMasuda AYuki HBetsunoh HYashi MFukabori YYoshida K, BMC Cancer, 14, 412, Jun. 2014

  DOI
• Prostate volume and biopsy tumor length are significant predictors for classical and redefined insignificant cancer on prostatectomy specimens in Japanese men with favorable pathologic features on biopsy, Yashi M, Mizuno TYuki HMasuda AKambara TBetsunoh HAbe HFukabori YMuraishi OSuzuki KNakazato YKamai T, BMC Urol, 14, 43, May 2014

  DOI
• Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report, Yuki H, Kamai TKubota KAbe HNishihara DMizuno TMasuda ABetsunoh HYashi MFukabori YYoshida K, Onco Targets Ther, 7, 289-295, Feb. 2014

  DOI
• Clinical significance of serum soluble T cell regulatory molecules in clear cell renal cell carcinoma, Masuda A, Arai KNishihara DMizuno TYuki HKambara TBetsunoh HAbe HYashi MFukabori YYoshida KKamai T, Biomed Res Int, 2014, 396064, 2014

  DOI
• 2(3), 122, Dec. 2013

  DOI
• Increased expression of system large amino acid transporter (LAT)-1 mRNA is associated with invasive potential and unfavorable prognosis of human clear cell renal cell carcinoma, Betsunoh H, Fukuda TAnzai NNishihara DMizuno TYuki HMasuda AYamaguchi YAbe HYashi MFukabori YYoshida KKamai T, BMC Cancer, 13, 509, Oct. 2013

  DOI
• Kidney transplantation of living unrelated and ABO-incompatible donor-recipient combinations, Ishikawa N, Yagisawa TKimura TSakuma YFujiwara TNukui AYashi M, Transplant Proc, 45(3), 1242-1244, Apr. 2013

  DOI
• Kidney transplantation of living unrelated donor-recipient combinations, Ishikawa N, Yagisawa TSakuma YFujiwara TKimura TNukui AYashi M, Transplant Proc, 44(1), 254-256, Jan. 2012

  DOI
• Kidney transplantation in patients with long-term (more than 15 years) prior dialysis therapy, Kimura T, Ishikawa NFujiwara TSakuma YNukui AYashi MYagisawa T, Transplant Proc, 44(1), 75-76, Jan. 2012

  DOI
• Acceptable residual renal function after retroperitoneoscopic kidney donation in elderly donors, Yashi M, Nukui AFujiwara TSakuma YIshikawa NKimura TIwabuchi TMurashi OYagisawa T, Transplant Proc, 42(10), 3989-3991, Dec. 2010

  DOI
• Strategic hand assistance for effective and safe retroperitoneoscopic live donor nephrectomy, Yashi M, Yagisawa TNukui AIshikawa NMiyamoto NSakuma YFujiwara TMuraishi O, Transplant Proc, 41(1), 88-90, Jan. 2009

  DOI
• Transplantation of ABO-incompatible and living unrelated donor-recipient combinations, Ishikawa N, Yagisawa TSakuma YFujiwara TNukui AYashi MMiyamoto N, Transplant Proc, 40(7), 2292-2293, Sep. 2008

  DOI
• Preemptive kidney transplantation of living related or unrelated donor-recipient combinations, Ishikawa N, Yagisawa TSakuma YFujiwara TNukui AYashi MMiyamoto N, Transplant Proc, 40(7), 2294-2296, Sep. 2008

  DOI
• Retroperitoneoscopic hand-assisted live-donor nephrectomy according to the basic principle of transplantation in donor kidney selection, Yashi M, Yagisawa TIshikawa NNukui AFujiwara TSakuma Y, J Endourol, 21(6), 589-594, Jun. 2007

  DOI
• 28(9), 1577-1583, Sep. 2015
• 24(1), 61-63, Mar. 2015
• 27(8), 1271-1273, Aug. 2014
• 21(1), 109-111, Mar. 2013
• 72(別冊 腎不全外科2012), 94-96, Apr. 2012
• 33, 49-54, Mar. 2011
• Clinical Significance of 18F-fluorodeoxyglucose and Glucose Transporter 1 mRNA in Clear Cell Renal Cell Carcinoma., Betsunoh Hironori;Sakamoto Setsu;Kaji Yasushi;Nukui Akinori;Kobayashi Minoru;Yashi Masahiro;Hayashi Keitaro;Anzai Naohiko;Kamai Takao, Anticancer research, 41(10), 5179-5188, Oct. 2021

  DOIPermalink
• Plasma progastrin-releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis-targeted agents in patients with metastatic castration-resistant prostate cancer., Yashi Masahiro;Nishihara Daisaku;Yokoyama Megumi;Fuchizawa Hirotaka;Okazaki Akihito;Takei Kohei;Suzuki Issei;Sakamoto Kazumasa;Kijima Toshiki;Kobayashi Minoru;Kamai Takao, Cancer reports (Hoboken, N.J.), e1762, 05 Dec. 2022

  DOIPermalink
• Transperitoneal laparoscopic umbilical resection of urachal remnants: a feasible surgical method., Yuki Hideo;Ohkubo Naoya;Kurashina Ryo;Sakamoto Kazumasa;Suzuki Issei;Takei Kohei;Betsunoh Hironori;Nukui Akinori;Yashi Masahiro;Kamai Takao, BMC urology, 23(1), 57, 04 Apr. 2023

  DOI
• Association between Immune Checkpoint Inhibitor Treatment Outcomes and Body Composition Factors in Metastatic Renal Cell Carcinoma Patients., Takei Kohei;Kijima Toshiki;Okubo Naoya;Kurashina Ryo;Kokubun Hidetoshi;Uematsu Toshitaka;Betsunoh Hironori;Yashi Masahiro;Kamai Takao, Cancers, 15(23), 26 Nov. 2023

  DOI

Review paper
• 50(2), 89-93, Dec. 2023

Case report
• [A Case of Secondary Syphilis Mimicking a Penile Cancer with Lymph Node Metastases, 69(7), 199-202, Jul. 2023
• 45, 107-111, Mar. 2023

Other
• 23(1), 66-69, Dec. 2011
• 57(3), 147-149, Mar. 2011
• 33(11), s188-s198, Sep. 2013

  DOI
• 26(8), 1299-1302, Aug. 2013
• 72(2), 195-198, Feb. 2012
• Editorial Comment to Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer., Yashi M, Int J Urol, 22(6), 561-562, Jun. 2015

  DOI
• 60(3), 412-419, Mar. 2015

Unclear
• Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels., Kobayashi Minoru;Kijima Toshiki;Yashi Masahiro;Kamai Takao, Prostate international, 11(1), 27-33, 24 Aug. 2022

  DOI

Presentations

• FGF7 as a candidate urine biomarker for prostate cancer detection., Fukabori Y, Yamazaki H, Yanagibayashi A, Yashi M, Abe H, Betsunoh H, Masuda A, Yuki H, Arai K, Kamai T, Apr. 2014, Poster presentation, The 29th Annual Congress of the European Association of Urology, True
• A practical training system of laparoscopic surgery, Yuki H, Nishihara D, Fuse M, Mizuno T, Masuda A, Betsuno H, Abe H, Yashi M, Fukabori Y, Yamanishi T, Yoshida K-I, Kamai T, Oct. 2013, Poster presentation, 31st world congress of endourology&SWL, True